WAT logo

Waters Corporation

WAT · What the business does, what can go wrong, and how options sellers approach it

What it does

Waters makes analytical instruments and the software and supplies that go with them. Its core products are liquid chromatography systems, which separate a mixture into its components, and mass spectrometry, which identifies those components by their mass. It also sells thermal analysis tools that measure how materials respond to heat.

Customers use these tools to learn what a sample contains and how pure or stable it is. Customers include pharmaceutical and biotech companies, industrial users such as food, environmental and chemical testers, and academic and government labs.

How it makes money

Waters earns revenue in two main ways. First, it sells instruments, which are a one-time purchase that tends to rise and fall with customer budgets. Second, it sells recurring items: chemical columns and other consumables, replacement parts, service contracts and software. Recurring revenue is generally steadier because labs keep running samples on installed instruments.

Once a lab validates a method on a Waters system, switching is costly and slow, which helps keep customers.

Why investors own it

  • A large installed base that generates repeat consumables and service demand.
  • Exposure to long-term drug development and quality-control testing, where precise measurement is required.
  • Switching costs that can support pricing and customer loyalty.
  • Cash generation from a business that does not need heavy capital spending.

What can go wrong

  • Instrument demand can slow when pharma or biotech cut spending or funding tightens.
  • Tariffs, currency swings and international exposure can pressure results.
  • Larger rivals in life science tools compete hard on technology and price.
  • Large acquisitions or mergers bring integration risk, and a bigger business may behave differently than the one investors first knew.

What to watch

  • Instrument versus recurring revenue trends
  • Orders and demand from pharma and biotech customers
  • Organic growth, which excludes currency and acquisitions
  • Operating margin
  • Progress on integrating any major combination

Options income angle

Options on WAT are generally available across several expirations, but liquidity is usually thinner than for mega-cap names, so spreads can be wide.

Implied volatility tends to rise ahead of quarterly earnings and on pharma spending news. The main caution: a sharp earnings gap can move the stock well past your strike, and the premium may not offset the loss.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 23, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Waters grew sales 7% in 2025, but the main story is the BDS Business acquisition, completed February 9, 2026. It brings $4.0 billion of assumed debt, an integration effort and expected cost savings. The 2025 results do not include BDS.

How the business did

  • Net sales rose 7% in 2025 after a flat 2024. Management cited strong demand across most regions and product lines. Sales to pharmaceutical customers rose 9%, and academic and government sales were flat.
  • Chemistry consumables (columns and testing kits) grew 12%, and service grew 7%. Waters instrument systems grew 7%, while the smaller TA segment (thermal analysis) fell 1%. China sales rose 10% after falling 10% in 2024.
  • Operating income was $803 million, down from $826 million. Management pointed to sales mix, pay raises, approximately $82 million of BDS deal and integration costs and $20 million of expenses for a new ERP system (the software that runs the company's books and operations). Net income per diluted share was $10.76, against $10.71 in 2024.
  • Operating cash flow was $653 million, down from $762 million, partly from $52 million of ERP costs and a final $24 million tax payment. Capital spending was $113 million. The company made no open market share repurchases in 2024 or 2025, and $1.0 billion of authorization remains.

Risks specific to this company

  • Acquisition debt: The company assumed $4.0 billion of loans. It plans to refinance the $3.5 billion tranche in the first quarter of 2026 with long-term bonds and repay the $500 million tranche early. The filing says there is no assurance the refinancing will be on reasonable terms or possible at all.
  • Integration and savings targets: The company expects cost synergies of approximately $200 million within three years and revenue synergies of approximately $290 million within five years. It warns these may be delayed or not achieved, and restructuring may disrupt operations.
  • Tax-related limits: A Tax Matters Agreement restricts stock issuance, stock purchases and some mergers for two years. If the company's actions cause the spin-off to become taxable, it would bear the resulting tax, which the filing expects would be material.
  • International and China exposure: Approximately 69% of 2025 net sales were outside the U.S. China demand fell in 2024 on weak economic conditions, tariffs and tighter government-funded purchasing. A February 20, 2026 Supreme Court ruling on tariffs adds uncertainty.
  • Customer and supply concentration: Approximately 59% of 2025 net sales went to pharmaceutical accounts. Some parts come from limited or single sources, and contract manufacturers in Singapore build LC instrument systems.
  • Singapore tax incentive: A 5% concessionary rate runs through March 31, 2026. If milestones are missed, prior benefits would be reversed at the 17% statutory rate.

What management is watching

  • Refinancing: Completing the bond refinancing of the $3.5 billion tranche and repaying the $500 million tranche early.
  • Integration: Site rationalization, procurement savings and streamlining of commercial, service and technology functions. BD will provide transition services for three months up to 24 months.
  • ERP rollout: Management anticipates spending approximately $130 million, of which $52 million was spent through the end of 2025.
  • Tariffs and trade policy: Management is evaluating actions to offset a portion of tariff effects and says it cannot guarantee a material impact will be avoided. It also notes changes in U.S. government funding and research grants.
  • Measures pointed to: Recurring revenues (chemistry plus service) rose 8%. Days sales outstanding was 84 days at December 31, 2025. Foreign currency is expected to be neutral to gross profit in 2026, and swap agreements are expected to lower net interest expense by approximately $11 million.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended October 3, 2026, filed November 10, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

The February 9, 2026 acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business (BDS) more than doubled revenue. Total net revenues were $1,767 million, up 121% from $800 million. Profit fell, though: operating income was $128 million versus $192 million, and net income was $81 million versus $149 million. The filing ties the drop to acquisition accounting charges, higher interest costs and integration spending.

How the business did

  • Revenue: BDS contributed $896 million in the quarter. Excluding BDS, legacy revenue rose 9% for the quarter and 10% for the nine months, with growth across all product lines and regions. Nine-month total net revenues were $4,678 million, up 110%. By segment, Analytical & Materials Sciences had $796 million (up 8%), Biosciences $396 million and Advanced Diagnostics $575 million.
  • Profit: Purchased intangibles amortization (the gradual expensing of the value assigned to acquired assets) was $244 million versus $12 million. Cost of revenue included $80 million of step-up expense, which comes from marking acquired inventory and equipment up to fair value. Interest expense, net was $53 million versus $22 million. Diluted earnings per share were $0.82 versus $2.50. For nine months the company reported an operating loss of $6 million and a net loss per diluted share of $1.37.
  • Margins: Analytical & Materials Sciences segment operating income was 35.3% of revenue versus 37.9%. Management cited sales mix, foreign currency, merit pay and product development costs.
  • Cash and capital: Operating cash flow for nine months was $315 million versus $488 million. The company cited $142 million of transaction and integration payments and $46 million of restructuring payments. It had $5.1 billion of outstanding debt and $593 million of cash, cash equivalents and investments. It made no open market share repurchases in 2026 and pays no dividends.
  • Unusual items: A workforce reduction affecting approximately 3% of employees cost $12 million in the quarter and $64 million for nine months.

What management is watching

  • Cost savings: The workforce reduction should deliver annual salary-related savings of approximately $120 million. Savings were $39 million through the third quarter, with approximately $67 million estimated for 2026.
  • Tariffs: After the Supreme Court invalidated tariffs issued under the International Emergency Economic Powers Act, the company may be eligible for refunds but has not recognized any material amounts. New tariffs were imposed under other legal authority. Management says its offsetting actions should mitigate a substantial portion of the impact, without assurances. Inventory rose partly from added safety stock.
  • Integration and debt: BD provides back-office services under a transition agreement for up to three years at roughly $90 million a year. The company says it can cover the $650 million of Senior Notes due in September 2027 with cash and its credit facility.
  • Outlook: The filing gives no full-year revenue or profit guidance. It points to legacy revenue growth excluding BDS and to BDS-related costs.

Follow WAT in Kortex

The Kortex app shows WAT's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.